Company ST Pharm Co.,Ltd.

Company ST Pharm Co.,Ltd.

A237690

KR7237690003

Pharmaceuticals

Analysts' Consensus

Equities

A237690

KR7237690003

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for ST Pharm Co.,Ltd.

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for ST Pharm Co.,Ltd.

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-02 EDT			5-day change	1st Jan Change
96,500 ^KRW	+8.67%		+12.60%	+42.33%

2023	ST Pharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
2021	ST Pharm Co.,Ltd. Announces Expansion of Oligonucleotide Facility	CI

STPharm Co.,Ltd. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The Company's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The Company distributes its products within domestic market and to overseas markets.

Number of employees: 645

KRW in Million	2022	Weight	2023	Weight	Delta
Raw Drug 88.3 %	209,270	83.9 %	251,559	88.3 %	+20.21%
Clinical Trial Trustee Research 11.7 %	40,052	16.1 %	33,433	11.7 %	-16.52%

KRW in Million	2022	Weight	2023	Weight	Delta
Switzerland 34.6 %	110,252	44.2 %	98,640	34.6 %	-10.53%
Other Countries 23.3 %	56,194	22.5 %	66,276	23.3 %	+17.94%
South Korea 18.2 %	52,569	21.1 %	51,952	18.2 %	-1.17%
United States 14.0 %	30,306	12.2 %	39,839	14.0 %	+31.45%
Belgium 9.9 %	-	-	28,285	9.9 %	-

Managers	Title	Age	Since
Gyeong-Jin Kim CEO	Chief Executive Officer	61	17-03-16
Kyung-Eun Jung CTO	Chief Tech/Sci/R&D Officer	63	-
Hyun-Min Lee BRD	Director/Board Member	51	19-03-04
Young-Jae Lee AUD	Comptroller/Controller/Auditor	57	-
Seok-Wu Choi PRN	Corporate Officer/Principal	56	-

Members of the board	Title	Age	Since
Gyeong-Jin Kim CEO	Chief Executive Officer	61	17-03-16
Hyeong-Jun An BRD	Director/Board Member	60	18-03-15
Hyun-Min Lee BRD	Director/Board Member	51	19-03-04
Dong-Pyo Kim BRD	Director/Board Member	67	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	18,933,904	10,093,588 ( 53.31 %)	0	53.31 %

Name	Equities	%	Valuation
DONG-A SOCIO HOLDINGS CO., LTD. 32.41 %	6,096,552	32.41 %	402 M ₩
Jung-Seok Kang 13.16 %	2,475,657	13.16 %	163 M ₩
National Pension Service of Korea 5.072 %	954,012	5.072 %	63 M ₩
Sooseok Foundation 0.9123 %	171,600	0.9123 %	11 M ₩
ST Pharm Co., Ltd. ESOA 0.5207 %	97,929	0.5207 %	6 M ₩
Gyeong-Jin Kim 0.3416 %	64,247	0.3416 %	4 M ₩
Nikko Asset Management Asia Ltd. 0.1068 %	20,080	0.1068 %	1 M ₩
Seok-woo Choi 0.1065 %	20,039	0.1065 %	1 M ₩
Soon-ki Jang 0.0218 %	4,101	0.0218 %	270 506 ₩
Korea Investment Management Co., Ltd. 0.009602 %	1,806	0.009602 %	119 126 ₩

ST Pharm Co., Ltd.

#802, Siheunggongdan 1-Na 231 Hyeomnyeok-ro

15086, Siheung

http://www.stpharm.co.kr

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

96,500 KRW

Average target price

105,556 KRW

Spread / Average Target

+9.38%

Consensus

Estimates Revisions

Company calendar

	1st Jan change	Capi.
ST PHARM CO.,LTD.	+42.33%	1.35B
ELI LILLY AND COMPANY	+26.08%	662B
NOVO NORDISK A/S	+21.31%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	289B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+4.60%	198B
ROCHE HOLDING AG	-10.59%	194B
AMGEN INC.	+8.08%	167B

Other Pharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals